Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | MAOA | P21397 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19289840 | 1.00 | HTT (0.64) | HTTALDH1A1MAOAMAOBBCHE | |
| SCHEMBL62691 | 1.00 | HTT (0.64) | HTTALDH1A1MAOAMAOBBCHE | |
| SCHEMBL172262 | 0.90 | MAOA (0.64) | HTTMAOAMAOBBCHEADRA2B | |
| SCHEMBL13911216 | 0.90 | MAOA (0.64) | HTTMAOAMAOBBCHEADRA2B | |
| SCHEMBL8517647 | 0.89 | HTT (0.56) | HTTALDH1A1MAOAMAOBBCHE | |
| SCHEMBL1327511 | 0.87 | HTT (0.56) | HTTALDH1A1MAOAMAOBBCHE | |
| SCHEMBL14930299 | 0.87 | HTT (0.56) | HTTALDH1A1MAOAMAOBBCHE | |
| SCHEMBL1327514 | 0.87 | HTT (0.56) | HTTALDH1A1MAOAMAOBBCHE | |
| SCHEMBL7780082 | 0.86 | ALDH1A1 (0.54) | HTTALDH1A1MAOAMAOBBCHE | |
| SCHEMBL18995758 | 0.85 | ALDH1A1 (0.60) | HTTALDH1A1MAOAMAOBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024234014-A1 | SUBLINGUAL SPRAY FORMULATIONS OF PSYCHEDELICS | SPIRITUS BIOSCIENCE, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20240122895-A1 | ENTACTOGEN-ASSISTED THERAPY FOR ALCOHOL USE DISORDER AND ADDICTION-RELATED CONDITIONS AND COMORBIDITIES | AWAKN LS EUROPE HOLDINGS LIMITED (IE) | 2024-04-18 | — | — | US | disclosed |
| WO-2024020572-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PTSD | NEW YORK STEM CELL FOUNDATION, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| EP-2861581-B1 | 1,2,3,4-Tetrahydroisoquinoline-pyrrolidine derivatives as antagonists of apoptosis (IAPs) for the treatment of cancer. | BRISTOL MYERS SQUIBB CO (US) | 2017-02-01 | — | — | EP | disclosed |
| US-20130296327-A1 | SUBSTITUTED HETEROCYLIC COMPOUNDS | INCYTE CORPORATION | 2013-11-07 | — | — | US | disclosed |
| US-8481732-B2 | Substituted heterocyclic compounds | INCYTE CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-8338591-B2 | 3-aryl-5,6-disubstituted pyridazines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-12-25 | — | — | US | disclosed |
| EP-1745024-B1 | 1-ARYL-4-SUBSTITUTED ISOQUINOLINES | NOVARTIS INT PHARM LTD (BM) | 2012-04-25 | — | — | EP | disclosed |
| EP-1565452-B1 | 3-SUBSTITUTED-6-ARYL PYRIDINES AS LIGANDS OF C5A RECEPTORS | NOVARTIS INT PHARM LTD (BM) | 2012-04-04 | — | — | EP | disclosed |
| US-8129395-B2 | 4,5-disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-03-06 | — | — | US | disclosed |
| EP-0927184-A1 | 3-SUBSTITUTED PYRIDO 4',3':4,5]THIENO 2,3-D]PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE | BASF AKTIENGESELLSCHAFT (DE) | 1999-07-07 | — | — | EP | disclosed |
| WO-1998011110-A1 | 3-SUBSTITUTED PYRIDO[4',3':4,5]THIENO[2,3-D]PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE | BASF AKTIENGESELLSCHAFT (DE) | 1998-03-19 | — | — | WO | disclosed |
| US-5690906-A | TETRALIN DERIVATIVES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1997-11-25 | — | — | US | disclosed |
| EP-0455510-B1 | Use of 5-HT1A receptor agonist compounds for inhibiting gastric acid secretion | LILLY CO ELI (US) | 1996-11-27 | — | — | EP | disclosed |
| EP-0697894-A4 | DOPAMINE D-3 AND SEROTONIN (5-HT 1A?) RECEPTOR LIGANDS AND IMAGING AGENTS | UNIV PENNSYLVANIA (US) | 1996-05-01 | — | — | EP | disclosed |
| EP-0697894-A1 | DOPAMINE D-3 AND SEROTONIN (5-HT 1A?) RECEPTOR LIGANDS AND IMAGING AGENTS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1996-02-28 | — | — | EP | disclosed |
| EP-0385658-B1 | Ring-substituted 2-amino 1,2,3,4-tetra-hydronaphthalenes and 3-aminochromanes | LILLY CO ELI (US) | 1994-12-28 | — | — | EP | disclosed |
| WO-1994022495-A1 | DOPAMINE D-3 AND SEROTONIN (5-HT1A) RECEPTOR LIGANDS AND IMAGING AGENTS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1994-10-13 | — | — | WO | disclosed |
| EP-0455510-A2 | Use of 5-HT1A receptor agonist compounds for inhibiting gastric acid secretion | ELI LILLY AND COMPANY (US) | 1991-11-06 | — | — | EP | disclosed |
| EP-0385658-A1 | Ring-substituted 2-amino 1,2,3,4-tetra-hydronaphthalenes and 3-aminochromanes | ELI LILLY AND COMPANY (US) | 1990-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296327-A1 | SUBSTITUTED HETEROCYLIC COMPOUNDS | HRH4, HRH2, HRH1 | HTT 560/4885ALDH1A1 1903/4885MAOA 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.